8-K: GoodRx Reports Mixed Results for Q4 and Full Year 2023, Announces New Share Repurchase Program

GoodRx's fourth quarter and full year 2023 results show revenue growth and improved profitability metrics, alongside a new $450 million share repurchase program.

Summary

• GoodRx released its financial results for the fourth quarter and full year 2023, showing a 7% increase in revenue to $196.6 million for the quarter and $750.3 million for the year.
• The company reported a net loss of $25.9 million for the quarter, but an adjusted net income of $31.1 million, and a net loss of $8.9 million for the full year, but an adjusted net income of $114.6 million.
• Adjusted EBITDA was $57.3 million for the quarter and $217.4 million for the full year, with margins of 29.1% and 28.6% respectively.
• The company exited the quarter with over 7 million consumers of prescription-related offerings.
• GoodRx announced a new stock repurchase program authorizing up to $450 million of Class A common stock repurchases.
• For the first quarter of 2024, GoodRx anticipates revenue between $195 million and $198 million, and for the full year 2024, revenue is expected to be around $800 million.
• The company expects Adjusted EBITDA for the full year 2024 to be approximately $250 million.

Sentiment

Score: 7

Explanation: The document presents a mixed picture with positive revenue growth and a new share repurchase program, but also includes a net loss and some challenges in specific revenue streams. The overall sentiment is cautiously optimistic.

Positives

• GoodRx experienced a 7% increase in revenue in the fourth quarter of 2023.
• The company's adjusted EBITDA margin for the fourth quarter was a strong 29.1%.
• GoodRx has a healthy cash balance of $672.3 million.
• The new $450 million share repurchase program signals confidence in the company's future.
• The company is projecting revenue growth for both the first quarter and full year of 2024.
• GoodRx is focused on disciplined capital allocation, including paying down debt and strategic M&A.

Negatives

• GoodRx reported a net loss of $25.9 million for the fourth quarter of 2023.
• Subscription revenue decreased by 6% in the fourth quarter due to the sunset of the Kroger Savings Club.
• Pharma manufacturer solutions revenue decreased by 2% in the fourth quarter due to the restructuring plan.
• Net cash provided by operating activities decreased to $15.9 million in Q4 2023 compared to $31.9 million in the same period last year.
• The company's full year net loss was $8.9 million.

Risks

• The company's revenue is impacted by the restructuring of its pharma manufacturer solutions offering.
• The sunset of the Kroger Savings Club is negatively impacting subscription revenue.
• The company is facing competition in the prescription savings market.
• There are risks associated with the company's reliance on third-party vendors and platforms.
• The company's future performance is subject to various market and economic factors.
• The company's ability to achieve its financial projections is subject to various uncertainties.

Future Outlook

GoodRx anticipates first quarter 2024 revenue between $195 million and $198 million, and full year 2024 revenue of approximately $800 million, with an Adjusted EBITDA of around $250 million. These growth rates are tempered by the impact of the pharma manufacturer solutions restructuring and the sunset of the Kroger Savings Club.

Management Comments

• Scott Wagner, Interim Chief Executive Officer, stated that the company ended the year strong with accelerating momentum in the business.
• Scott Wagner highlighted the company's focus on driving prescription-savings events through retail partnerships and integrated savings programs.
• Karsten Voermann, Chief Financial Officer, mentioned that the first quarter guide includes the impact of recent system outages at UnitedHealth Group, which are not expected to have a material impact.
• Karsten Voermann emphasized the company's strong balance sheet and liquidity position, and its focus on disciplined capital deployment.

Industry Context

GoodRx operates in the competitive healthcare technology sector, focusing on prescription savings. The company's performance is influenced by factors such as relationships with pharmacy benefit managers, pharmacies, and pharma manufacturers. The company's restructuring efforts and focus on core offerings reflect a broader trend in the industry towards efficiency and profitability.

Comparison to Industry Standards

• GoodRx's adjusted EBITDA margin of 29.1% in Q4 2023 is relatively strong compared to other healthcare technology companies, but it is important to compare this to companies with similar business models.
• Companies like SingleCare and Optum Rx also operate in the prescription savings space, and their financial results would be relevant for comparison.
• GoodRx's revenue growth of 7% in Q4 2023 is moderate, and it is important to compare this to the growth rates of other companies in the healthcare technology sector.
• The company's share repurchase program is a common practice among publicly traded companies, but the size of the program ($450 million) is significant and indicates confidence in the company's future.

Stakeholder Impact

• Shareholders will benefit from the share repurchase program and the company's focus on creating shareholder value.
• Consumers will continue to have access to prescription savings through the GoodRx platform.
• Employees may be impacted by the company's restructuring and cost reduction efforts.
• Retail partners will continue to benefit from the company's relationships and integrated savings programs.

Next Steps

• GoodRx will continue to execute its strategic priorities, including investing for profitable growth, paying down debt, and strategic M&A.
• The company will continue to repurchase shares under the new stock repurchase program.
• GoodRx will focus on driving prescription-savings events and expanding its integrated savings program.
• The company will continue to monitor the impact of the UnitedHealth Group system outages.

Key Dates

Keywords

GoodRx, prescription savings, financial results, revenue, EBITDA, share repurchase, healthcare, pharmacy, stock